drugset
drugset / Trial / NCT04544592

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

NCT04544592 ↗

Phase 1/2 Recruiting 45 enrolled University of Colorado, Denver Children's Hospital Colorado · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally with the goals to expedite infusion to wider patient inclusion that includes those who were previously excluded, such as pediatric patients with B-cell NHL and patients in primary relapse.

Timeline

Start
2021-03-10
Primary completion
2026-06
Completion
2026-07

Drugs

EvaluationDrugModalityDoseRoute
Subject CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells Cell therapy — —

Indications

B-cell acute lymphoblastic leukemia